00566nas a2200205   4500008004100000022001400041245003800055210003500093260001600128300001400144490000800158100002100166700002000187700001800207700001900225700001700244700002100261700002200282856005600304       2020                        eng d  a2242-328100aLymphatics and the eye. [Finnish]0 aLymphatics and the eye Finnish  c2020/02/10/  a1777-17880 v1361 aGucciardo, Erika1 aLehti, Timo, A.1 aKorhonen, Ani1 aSalvén, Petri1 aLehti, Kaisa1 aJeltsch, Michael1 aLoukovaara, Sirpa  uhttps://www.duodecimlehti.fi/lehti/2020/16/duo1573900962nas a2200181   4500008004100000245007000041210006900111260000900180300000900189490000700198520040300205100002400608700002100632700002300653700001600676700002500692856006300717       2016                        eng d00aLymphatic Vessels in Regenerative Medicine and Tissue Engineering0 aLymphatic Vessels in Regenerative Medicine and Tissue Engineerin  c2016  a1-130 v223 aOnce a DOI is available for this article, the final publication will be available from Mary Ann Liebert, Inc., publishers at http://dx.doi.org/10.1089/TEN.TEB.2016.0034. The postprint manuscript is available from <a href="sites/jeltsch.org/files/Schaupper2016_TissueEngineering_Review.pdf">here</a> and for the next 30 days also from the publisher via this bit.ly shortcut: http://bit.ly/1VKjjMk.
1 aSchaupper, Mira, V.1 aJeltsch, Michael1 aRohringer, Sabrina1 aRedl, Heinz1 aHolnthoner, Wolfgang  uhttp://online.liebertpub.com/doi/10.1089/ten.TEB.2016.003403405nas a2200109   4500008004100000245004400041210004400085260006500129520301700194100002103211856006303232       2015                        eng d00aLymphangiogenesis in Health and Disease0 aLymphangiogenesis in Health and Disease  aLausanne, SwitzerlandbEuropean Group of Lymphologyc06/20153 aDespite the intensive research on the lymphangiogenic VEGF-C/VEGFR-3 signaling pathway in the last two decades, new and unexpected findings do not cease to be made. Diseases that involve the lymphatic system have helped to uncover mechanisms of its normal functioning and development.

A recent example of new basic knowledge that resulted from the investigation of a human disease is Hennekam lymphangiectasia­ lymphedema syndrome (OMIM 235510). It is an autosomal recessive condition, which can co-segregate with mutations in the collagen- and calcium-binding EGF domains 1 (CCBEJ) or the protocadherin Fat 4 (FAT4) gene.

Both CCBEI and the lymphangiogenic vascular endothelial growth factor C (VEGF-C) are necessary for the early lymphatic development, namely for the budding and migration of endothelial cells from the cardinal vein (CV) and for the formation of the early lymphatic structures. These processes fail in embryos deficient of either Ccbel or Vegfc. In Vegfc-deficient embryos pro-spective lymphatic endothelial cells fail to sprout from the CV, whereas in Ccbel-deficient embryos, the sprouting is abnormal and does not result in the formation of discrete lymphatic structures.

The similar phenotypes of Ccbe- and Vegfc-deficient embryos result from the interaction of CCBEI with the VEGF-C growth factor signaling pathway, which is critical in embryonic and adult lymphangiogenesis. VEGF-C is synthesized as an inactive proprotein and needs to be processed by at least two distinct proteases to become fully active. The presence of CCBEI promotes VEGF-C by two independent mechanisms. The C-terminal domain of CCBEI boosts VEGF-C function via increased ADAMTS3-mediated proteolytic activation of VEGF-C, while the N-terminal domain of CCBEI concentrates pro-VEGF-C on endothelial cell-surfaces, where it can be activated in situ by cell-surface associated proteases. Both mechanisms lead to increased VEGFR-3 signaling and increased lymphangiogenesis.

These results show that CCBEI is integral to lymphangiogenesis by increasing the levels of active VEGF-C at the endothelial cell surface. Because some forms of lymphedema appear to be treatable by increasing the amount of VEGFR-3 signaling, the first clinical trials designed around a pro-lymphangiogenic concept use VEGF-C. The goal in these trials is to enhance the integration of lymph nodes into the lymphatic vasculature after autologous transfer to treat postmastectomy lymphedema. On the other hand, VEGF-C­ induced lymphangiogenesis enhances tumor metastasis and VEGF-C-induced tumor angiogenesis in several mouse models. Blocking VEGF-C might be for these reasons an attractive adjuvant treatment to supplement current cancer treatment regimens that include anti­ angiogenic drugs. The right balance between pro- and anti-Iymphangiogenic stimuli might therefore differ between individuals and CCBEI is an attractive drug target to adjust pro- and anti-Iymphangiogenic stimuli by tuning the rate of VEGF-C activation.
1 aJeltsch, Michael  uhttp://www.eurolymphology.org/JOURNAL/VOL26-N72-2015/#p=1001909nas a2200193   4500008004100000245014000041210006900181260001200250300001200262490000700274520124700281653001901528653002201547653001101569653001101580100001801591700002101609856008501630       2013                        eng d00aThe lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Basic principles and embryonic development. [bilingual: English, German].0 alymphangiogenic growth factors VEGFC and VEGFD Part 1 Basic prin  c05/2013  a30 - 370 v173 aVEGF-C and VEGF-D are the two central signaling molecules that stimulate the develop- ment and growth of the lymphatic system. Both belong to the vascular endothelial growth factor (VEGF) protein family, which plays important roles in the growth of blood vessels (angiogenesis) and lymphatic vessels (lymphangiogenesis). In mammals, the VEGF family comprises five members: VEGF-A, PlGF, VEGF-B, VEGF-C and VEGF-D. The family was named after VEGF-A, the first member to be discovered. VEGF-C and VEGF-D form a subgroup within this family in terms of function and structure. Their distinctive biosynthesis differentiates them from the other VEGFs: they are produced as inactive precursors and need to be activated by proteolytic removal of their long N- and C-terminal propeptides. Unlike the other VEGFs, VEGF-C and VEGF-D are direct stimulators of lymphatic vessel growth. They exert their lymphangiogenic function via VEGF receptor 3, which is expressed in the adult organism almost exclusively on lymphatic endothelial cells. In this review, we provide an overview of the VEGF protein family and their receptors. We focus on the lymphangiogenic VEGF-C and VEGF-D, discussing their biosynthesis and their role in embryonic lymphangiogenesis.10agrowth factors10aLymphangiogenesis10aVEGF-C10aVEGF-D1 aKrebs, Rainer1 aJeltsch, Michael  uhttp://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Lymphforsch2013_30.pdf